Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., multi-specific antibodies or antigen binding fragments thereof) that can bind to the GPA33 protein. The multi-specific antibodies of the present technology are useful in methods for detecting and treating a GPA33-associated cancer in a subject in need thereof.

Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of L1-CAM protein. The antibodies of the present technology are useful in methods for detecting and treating a L1-CAM-positive cancer in a subject in need thereof.

Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g antibodies or antigen binding fragments thereof) that can bind to the PSMA protein. The antibodies of the present technology are useful in methods for detecting and treating a PSMA-associated pathology in a subject in need thereof.

Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.

Abstract: The present disclosure relates generally to methods for determining whether a patient will show an enhanced immunogenic response to vaccines when using ?-glucan as a vaccine adjuvant.

Abstract: The present disclosure provides ex vivo armed T cell (EAT) compositions that comprise multi-specific (e.g., bispecific) antibodies that bind to CDS and at least one additional target antigen (e.g., antigen that is expressed by tumor cells and/or a DOTA label). The EAT compositions of the present technology are useful for adoptive immunotherapy in a subject in need thereof.

Abstract: The present technology relates to the use of protein conjugates including a self-assembly and disassembly (SADA) polypeptide and a GD2-specific antigen binding domain for preventing or mitigating off-target tissue toxicity, such as brain, kidney, and/or myeloid damage, in a subject undergoing targeted alpha radioimmunotherapy. Also disclosed herein are pretargeted radioimmunotherapy (PRIT) methods that improve the durability of the anti-GD2-SADA conjugate anti-tumor response in vivo.

Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CD3 protein. The antibodies of the present technology are useful in methods for detecting and treating cancer or a CD3 -associated pathology in a subject in need thereof.

Abstract: The present invention relates to compositions and methods employing conjugates that include a self-assembly and disassembly (SADA) polypeptide and a binding domain. The present invention encompasses the recognition that conjugates with a SADA polypeptide have certain improved biological properties. SADA-conjugates are described, along with uses thereof (e.g., as therapeutic or diagnostic agents) and methods of manufacture.

Abstract: The present disclosure provides compositions and methods for the detection, and treatment of cancer. Specifically, the compositions of the present technology include multimodal fluorine-cyanine-DOTA-hapten compositions that may be complexed with a radioisotope (e.g., 175Lu). Also disclosed herein are methods of using the fluorine-cyanine-DOTA-hapten compositions of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.

Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of L1-CAM protein. The antibodies of the present technology are useful in methods for detecting and treating a L1-CAM-positive cancer in a subject in need thereof.

Abstract: The present invention relates to compositions and methods employing conjugates that include a self-assembly and disassembly (SADA) polypeptide and a binding domain. The present invention encompasses the recognition that conjugates with a SADA polypeptide have certain improved biological properties. SADA-conjugates are described, along with uses thereof (e.g., as therapeutic or diagnostic agents) and methods of manufacture.

Abstract: Provided are anti-CD33 antibody agents, including anti-CD33 antibody agents in an IgG-scFv format. Various methods and reagents related thereto are also provided, including for example for the detection, prevention, and/or therapeutical treatment of CD33-related diseases, in particular, leukemias such as AML.

Abstract: The present technology relates generally to the preparation of immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that specifically bind STEAP1 protein and uses of the same. In particular, the present technology relates to the preparation of STEAP1 binding antibodies and their use in detecting and treating STEAP1-associated cancers.

Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CDS 3 protein. The antibodies of the present technology are useful in methods for detecting and treating Alzheimer's disease or a CDS 3-associated cancer in a subject in need thereof.

Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CDS 3 protein. The antibodies of the present technology are useful in methods for detecting and treating Alzheimer's disease or a CD33-associated cancer in a subject in need thereof.

Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CD 19 protein. The antibodies of the present technology are useful in methods for detecting and treating a CD 19- associated autoimmune disease or a CD19-associated cancer in a subject in need thereof.

Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CD22 protein. The antibodies of the present technology are useful in methods for detecting and treating a CD22-associated cancer, a CD22-associated autoimmune disease, or a CD22-associated allergy in a subject in need thereof.

Abstract: The present disclosure relates generally to complexes comprising an interleukin-15 (“EL-15”) polypeptide chain non-covalently bonded to an IL-15 receptor ?-Fc fusion polypeptide (“IL-15R?-Fc”), and multimers (e.g., trimers) thereof. The complexes of the present technology are useful in methods for enhancing immune cell function and immunotherapy in a patient in need thereof. Also provided herein are methods for preventing or treating a disease or condition in which enhancing IL-15-mediated function is beneficial (such as cancer, infectious diseases, immunodeficiencies and leukopenia) in a patient in need thereof.

Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., heterodimeric trivalent/tetravalent multispecific antibodies) that specifically bind to three or four distinct target antigens. The immunoglobulin-related compositions described herein are useful in methods for detecting and treating cancer in a subject in need thereof.